Cronos Group Announces $30 Million Bought Deal

Cronos Group Inc.  (PRMCF) announced that it has entered into a letter of engagement with PI Financial Corp.  as lead underwriter for a syndicate of other underwriters to purchase for resale 3,428,572 common shares of  Cronos on a “bought deal” basis  at a price per share of $8.75 for total gross proceeds of $30,000,005.00. The deal is expected to close on or about January 27.

According to the company statement, the underwriters will have an option to increase the size of the offering by up to 15% unless the offering size is increased, in which case the overallotment option will be 15% of the increased Offering. Cronos Group plans to use the proceeds for general corporate purposes, to fund growth, and for research and development.

Cronos Group is a geographically diversified and vertically integrated cannabis company that operates two wholly-owned Licensed Producers regulated within Health Canada’s Access to Cannabis for Medical Purposes Regulations and holds a portfolio of minority investments in other Licensed Producers. The Company’s flagship LPs, Peace Naturals Project Inc. ( Ontario ) and Original BC Ltd. ( British Columbia ), are collectively situated on over 125 acres of agricultural, licensed land. Cronos Group is focused on building an international iconic brand portfolio, providing patients with personalized care and creating value for our shareholders.

Just last week, the company announced that its first shipment of Peace Naturals branded products to G. Pohl-Boskamp GmbH & Co. KG became available for sale across retail locations throughout Germany. Pohl-Boskamp is an international pharmaceutical manufacturer with distribution into over 12,000 pharmacies in Germany.  Pohl-Boskamp’s distribution network provides Cronos access to patients with insurance coverage for medicinal cannabis. “This marks a key milestone for Cronos by solidifying the largest international distribution platform in the industry and providing an unprecedented supply of high-quality medical cannabis products to German patients,” said Mike Gorenstein, CEO of Cronos.

The stock was lately trading at $7.72 on the OTC Marketplace. This is at its 52-week high, which has been in a range of 29 cents to $7.21.

Debra Borchardt

Debra Borchardt is the CEO, Co-Founder, and Editor-In-Chief of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Masters degree in Business Journalism from New York University.

Leave a Reply

Your email address will not be published. Required fields are marked *

Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 2 days

Happy Friday! Marijuana Money July 23, 2021

@GreenMarketRpt – 4 days

RT : I spoke with to discuss cannabis stock options worth consideration, and why U.S. MSOs pique his interest…

Back to Top